JP2019522039A5 - - Google Patents

Download PDF

Info

Publication number
JP2019522039A5
JP2019522039A5 JP2019504932A JP2019504932A JP2019522039A5 JP 2019522039 A5 JP2019522039 A5 JP 2019522039A5 JP 2019504932 A JP2019504932 A JP 2019504932A JP 2019504932 A JP2019504932 A JP 2019504932A JP 2019522039 A5 JP2019522039 A5 JP 2019522039A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
oxazepan
ethyl
carboxamide
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019504932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019522039A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/044343 external-priority patent/WO2018022978A1/en
Publication of JP2019522039A publication Critical patent/JP2019522039A/ja
Publication of JP2019522039A5 publication Critical patent/JP2019522039A5/ja
Priority to JP2022075836A priority Critical patent/JP2022115951A/ja
Priority to JP2024174121A priority patent/JP2025000959A/ja
Pending legal-status Critical Current

Links

JP2019504932A 2016-07-29 2017-07-28 気管支拡張症の処置のための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド Pending JP2019522039A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022075836A JP2022115951A (ja) 2016-07-29 2022-05-02 気管支拡張症の処置のための特定の（２ｓ）－ｎ－［（１ｓ）－１－シアノ－２－フェニルエチル］－１，４－オキサゼパン－２－カルボキサミド
JP2024174121A JP2025000959A (ja) 2016-07-29 2024-10-03 気管支拡張症の処置のための特定の（２ｓ）－ｎ－［（１ｓ）－１－シアノ－２－フェニルエチル］－１，４－オキサゼパン－２－カルボキサミド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662368400P 2016-07-29 2016-07-29
US62/368,400 2016-07-29
PCT/US2017/044343 WO2018022978A1 (en) 2016-07-29 2017-07-28 Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating bronchiectasis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022075836A Division JP2022115951A (ja) 2016-07-29 2022-05-02 気管支拡張症の処置のための特定の（２ｓ）－ｎ－［（１ｓ）－１－シアノ－２－フェニルエチル］－１，４－オキサゼパン－２－カルボキサミド

Publications (2)

Publication Number Publication Date
JP2019522039A JP2019522039A (ja) 2019-08-08
JP2019522039A5 true JP2019522039A5 (https=) 2020-08-27

Family

ID=61011892

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019504932A Pending JP2019522039A (ja) 2016-07-29 2017-07-28 気管支拡張症の処置のための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド
JP2022075836A Pending JP2022115951A (ja) 2016-07-29 2022-05-02 気管支拡張症の処置のための特定の（２ｓ）－ｎ－［（１ｓ）－１－シアノ－２－フェニルエチル］－１，４－オキサゼパン－２－カルボキサミド
JP2024174121A Pending JP2025000959A (ja) 2016-07-29 2024-10-03 気管支拡張症の処置のための特定の（２ｓ）－ｎ－［（１ｓ）－１－シアノ－２－フェニルエチル］－１，４－オキサゼパン－２－カルボキサミド

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022075836A Pending JP2022115951A (ja) 2016-07-29 2022-05-02 気管支拡張症の処置のための特定の（２ｓ）－ｎ－［（１ｓ）－１－シアノ－２－フェニルエチル］－１，４－オキサゼパン－２－カルボキサミド
JP2024174121A Pending JP2025000959A (ja) 2016-07-29 2024-10-03 気管支拡張症の処置のための特定の（２ｓ）－ｎ－［（１ｓ）－１－シアノ－２－フェニルエチル］－１，４－オキサゼパン－２－カルボキサミド

Country Status (6)

Country Link
US (6) US20180028541A1 (https=)
EP (1) EP3490566A4 (https=)
JP (3) JP2019522039A (https=)
KR (4) KR20250107292A (https=)
CN (1) CN109789150A (https=)
WO (1) WO2018022978A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (https=) 2014-01-24 2018-02-24
KR20250107292A (ko) * 2016-07-29 2025-07-11 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
AU2019217870A1 (en) * 2018-02-07 2020-08-27 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating ANCA associated vasculitides
KR20250002710A (ko) 2018-03-01 2025-01-07 아스트라제네카 에이비이 (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를포함하는 약학 조성물
AU2019306532A1 (en) 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis
US20210252015A1 (en) * 2018-07-17 2021-08-19 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating inflammatory bowel disease
CN116157687A (zh) 2020-07-20 2023-05-23 英斯梅德股份有限公司 用于提取嗜中性粒细胞丝氨酸蛋白酶以及治疗二肽基肽酶1介导的病症的方法
US20240150335A1 (en) * 2021-02-05 2024-05-09 Medshine Discovery Inc. Fused ring derivatives containing 1,4-oxazepane
WO2022232420A1 (en) * 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
US20240226112A1 (en) * 2021-04-29 2024-07-11 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis
CN115925696A (zh) * 2021-10-29 2023-04-07 瑞石生物医药有限公司 一种1-氰基-2-苯基乙基甲酰胺衍生物及其用途
CN116332937B (zh) * 2021-12-23 2026-04-10 杭州邦顺制药股份有限公司 二肽基肽酶ⅰ抑制剂及其用途
EP4450497A4 (en) * 2022-01-11 2025-11-26 Shanghai Yidian Pharmaceutical Tech Development Co Ltd NITRILE PEPTIDYL COMPOUND AND ITS USES
EP4479059A4 (en) * 2022-02-16 2026-01-28 Insmed Inc CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVE
CN115785083A (zh) * 2022-12-27 2023-03-14 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂及其制备方法
EP4646265A1 (en) 2023-01-06 2025-11-12 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof
JP2026510407A (ja) * 2023-03-23 2026-04-02 ハイスコ ファーマスーティカル プライベート リミテッド ジペプチジルペプチダーゼ小分子阻害剤を含む医薬組成物
KR102951779B1 (ko) 2023-08-31 2026-04-14 서울대학교병원 비결핵항산균 질환 및 기관지확장증의 진단을 위한 바이오마커 조성물
WO2025231041A1 (en) * 2024-04-30 2025-11-06 Renovion, Inc. Methods for reducing symptoms in subjects suffering from bronchiectasis and other pulmonary diseases
WO2025250560A1 (en) * 2024-05-28 2025-12-04 Insmed Incorporated Methods for treating bronchiectasis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0817311A2 (pt) * 2007-09-25 2015-03-17 Novartis Ag Tratamento de doenças pulmonares com medicamentos em aerossol tais como a vancomicina
CN102574830A (zh) * 2009-05-07 2012-07-11 阿斯利康(瑞典)有限公司 取代的1-氰基乙基杂环基甲酰胺化合物750
WO2010142985A1 (en) * 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
JP6473738B2 (ja) * 2013-04-01 2019-02-20 パルマトリックス，インコーポレイテッド チオトロピウム乾燥粉末
NO2699580T3 (https=) * 2014-01-24 2018-02-24
SMT202000516T1 (it) * 2014-05-15 2020-11-10 Insmed Inc Metodi per trattamento di infezioni micobatteriche polmonati non tubercolari
CA2965566A1 (en) * 2014-11-14 2016-05-19 Boehringer Ingelheim International Gmbh Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (sstr4) agonists
KR20250107292A (ko) * 2016-07-29 2025-07-11 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
KR20250002710A (ko) * 2018-03-01 2025-01-07 아스트라제네카 에이비이 (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를포함하는 약학 조성물

Similar Documents

Publication Publication Date Title
JP2019522039A5 (https=)
Vinh et al. Linezolid: a review of safety and tolerability
JP7221922B2 (ja) 組み合せ抗細菌組成物および短期抗細菌レジメン
Williams et al. Sterilizing activities of novel combinations lacking first-and second-line drugs in a murine model of tuberculosis
Condos et al. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis
JP2012523437A5 (https=)
MX2022011431A (es) Compuesto de oxazolidinona y metodos de uso de este como agente antibacteriano.
Chen et al. High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: case report
JP2021536504A5 (https=)
JP2020504154A (ja) 細菌感染症を処置する方法
Singh et al. Chemotherapeutic efficacy of thioridazine as an adjunct drug in a murine model of latent tuberculosis
US10752621B2 (en) Oxazolidinone compounds and methods of use thereof as antibacterial agents
US20220235047A1 (en) A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE
US11931344B2 (en) Sphingosine pathway modulating compounds for the treatment of coronavirus infection
JP2021102605A5 (https=)
Burgos et al. The activity of several newer antimicrobials against logarithmically multiplying M. leprae in mice
Latterell et al. Synthesis and evaluation of novel oxanthrene scaffold-derived oxazolidinone antibiotics with potent antitubercular activity and low cellular toxicity
CN113577084A (zh) 包含抗菌剂的药物组合物
KR20240090712A (ko) Spr720의 인간 유효 용량 및 투여 스케줄
JPWO2022232573A5 (https=)
RU2831120C2 (ru) Способы лечения микобактериальных инфекций с применением тетрациклиновых соединений
Foraida et al. 24 Global Drug Pipeline for Tuberculosis Treatment
Hands et al. 731. Pharmacokinetics of Gepotidacin (GSK2140944) in Subjects with Hepatic Impairment
NZ763060B2 (en) Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia
Lamichhane et al. Emerging Therapies